This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth

JW Asset Management sold 83,600 shares of Liquidia in Q1, trimming its stake to 16,176 shares worth $610,482 and reducing position value by $2.83 million. The sale lowered Liquidia to 0.25% of JW Asset Management's $243.51 million in reportable U.S. equity assets, but the move appears to be profit-taking after a 175% one-year share price surge rather than a full exit. Liquidia remains supported by improving fundamentals, including $148.3 million in 2025 net product sales and a second consecutive profitable quarter, with first-quarter earnings due next.

Analysis

JW Asset’s trim reads as a classic post-rerating de-risk rather than a thesis break. The important signal is not the sale itself but the willingness to keep a residual stake after a multi-bagger: that usually means the market has moved from “prove the product” to “prove durable operating leverage,” where incremental disappointments now matter more to valuation than headline growth.

The second-order dynamic is that Liquidia is transitioning from binary clinical/speculative ownership into a commercial-execution story. That tends to compress multiple expansion unless the next few quarters show prescription growth accelerating faster than operating costs; if sales inflect but SG&A stays sticky, the stock can look optically cheap on revenue while still being fundamentally over-earning expectations. In other words, the burden shifts from launch enthusiasm to evidence of repeatable payer access, refill behavior, and margin expansion.

Catalyst risk is front-loaded into the next earnings print and the following 60-90 days. A clean quarter could force underexposed funds to chase, but any slowdown in net sales growth or commentary around normalization after launch would likely trigger a sharp multiple reset because the stock has already priced in a lot of commercial success. The key contrarian point is that the best buyers may be those who want exposure to rare-disease commercialization, while the best sellers are the investors who entered before the market recognized YUTREPIA as a real revenue asset.

Key Decisions for Investors

• Tactically avoid chasing LQDA ahead of earnings; wait for post-print confirmation of prescription momentum and cash burn. The setup is asymmetric to the downside if growth decelerates, even modestly.
• If already long LQDA, trim 25-50% into strength into the event and retain a smaller core only if management guides to sustained prescription acceleration. Risk/reward has shifted from venture-style upside to execution-driven multiple support.
• Consider a pairs trade: long a higher-quality profitable commercial biotech with durable free-cash-flow conversion vs. short LQDA into the print. The thesis is that execution dispersion widens once the market starts discriminating between launch success and margin durability.
• For short-term traders, buy downside protection via LQDA puts around the catalyst rather than outright shorting. The stock can remain momentum-driven, but event risk is now more likely to produce a sharp gap lower than a gradual drift.
• Watch for follow-through selling from concentrated holders over the next 1-2 quarters; if multiple funds start reducing, that would confirm the “profit-taking after re-rating” pattern and extend downside beyond the earnings window.